Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Ascletis Reports Strong Phase II Data for Hepatitis C Drug

publication date: Mar 17, 2015
Ascletis, a US-China pharma, reported that one of its two potential treatments for hepatitis C, ASC08, a direct acting antiviral agent that Ascletis in-licensed from Roche, produced positive results in a Phase II trial. The trial enrolled Taiwanese patients. After 12 weeks of treatment, the SVR12 (sustained viral response) rate observed in genotype 1 non-cirrhotic Taiwanese patients was 94% and 100% in genotype 1b non-cirrhotic Taiwanese patients. Ascletis pointed out that Genotype 1b accounts for 98% of genotype 1 and 57% of all hepatitis C patients in mainland China. More details....

Stock Symbol: (SIX: ROG)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here